Karmustin Tillomed Pharma

Carmustine, the active ingredient in Karmustin Tillomed Pharma, is a nitrosourea alkylating agent presented as an intravenous formulation for use in oncology. It is employed in the treatment of high‑grade gliomas, primary central nervous system lymphoma, Hodgkin's lymphoma, melanoma and other solid tumours as part of combination chemotherapy.

GNH USA supplies Karmustin Tillomed Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Carmustine is used in oncology to target rapidly dividing cancer cells across several tumour types. - High‑grade gliomas (e.g., glioblastoma multiforme): improves survival when combined with radiotherapy. - Primary central nervous system lymphoma: provides disease control as part of multi‑agent regimens. - Hodgkin's lymphoma: used in salvage chemotherapy protocols. - Melanoma: contributes to tumour reduction in combination therapy. - Other solid tumours: incorporated into combination chemotherapy to enhance cytotoxic effect.

Carmustine can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported. - Myelosuppression: reduced blood cell counts leading to anemia, neutropenia, or thrombocytopenia. - Fatigue: persistent tiredness during treatment. - Alopecia: hair loss affecting scalp and body hair. - Increased infection risk: due to immune suppression. - Mild liver enzyme elevation: transient hepatic changes.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe bone marrow suppression: profound pancytopenia. - Hepatic dysfunction: significant liver injury. - Secondary malignancies: risk of therapy‑related cancers. - Seizures: neurologic events in susceptible patients. - Renal impairment: rare kidney function decline.

Carmustine requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: check hepatic enzymes prior to each cycle. - Evaluate pulmonary status: baseline and periodic lung function tests are advised. - Avoid concurrent radiotherapy to the same field: increased risk of tissue necrosis. - Use protective equipment: handle the drug in a controlled environment to prevent exposure. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Carmustine may interact with other medications, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent alkylating agents: additive bone marrow toxicity. - Radiation therapy to the same site: heightened risk of tissue damage. - Live vaccines: increased infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., phenytoin): may affect hepatic metabolism. - Warfarin: potential for altered anticoagulant effect. - Broad‑spectrum antibiotics: may exacerbate myelosuppression. - Other myelosuppressive agents: require dose adjustments and close monitoring. - Immunosuppressants: increased infection susceptibility.